Semaglutide

📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.

What Is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed as a structural analog of the endogenous incretin hormone GLP-1. It is a 31-amino-acid peptide built on the GLP-1(7-37) backbone with three engineered modifications that distinguish it from earlier short-acting analogs: an α-aminoisobutyric acid (Aib) substitution at position 8 that resists DPP-4 cleavage, an arginine substitution at position 34 to prevent off-target acylation, and a C18 fatty diacid attached at lysine 26 via a γ-glutamic acid and two 2-(2-aminoethoxy)ethoxyacetic acid (AEEA) spacers. The fatty-acid tether drives strong reversible binding to circulating albumin, extending the plasma half-life to approximately 165 hours and making semaglutide the longest-acting GLP-1 agonist developed to date for once-weekly subcutaneous dosing in published studies. Semaglutide’s peptide sequence and molecular structure are well-characterised: empirical formula C₁₈₇H₂₉₁N₄₅O₅₉, average molecular weight 4113.58 Da. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Pharmaceutical semaglutide is approved by the FDA, EMA, and MHRA under the brand names Ozempic (subcutaneous, type 2 diabetes), Wegovy (subcutaneous, chronic weight management), and Rybelsus (oral, type 2 diabetes). For a deep dive on mechanism, pharmacokinetics, and head-to-head trial data, see our full Retatrutide vs Tirzepatide guide and the broader peptides catalog.

Mechanism of Action — GLP-1 Receptor Signaling Across Three Tissue Compartments

What makes semaglutide more pharmacologically interesting than earlier GLP-1 analogs (liraglutide, exenatide) is the combination of high receptor selectivity with a half-life long enough to maintain near-continuous receptor occupancy. Published studies has mapped its activity across three distinct tissue compartments, each contributing to the observed metabolic phenotype:

• Pancreatic β-cell — glucose-dependent insulin secretion — Semaglutide binds the GLP-1 receptor on pancreatic β-cells, activating Gα_s-coupled adenylyl cyclase, raising intracellular cAMP and PKA / EPAC2 signaling. The downstream effect is a glucose-dependent potentiation of insulin secretion: hypoglycaemia is rare because the signal requires elevated intracellular glucose to translate into insulin release. Parallel suppression of glucagon secretion from α-cells contributes to lower fasting hepatic glucose output in diabetes models.
• Central nervous system — appetite and satiety circuits — Semaglutide crosses the blood-brain barrier sufficiently to activate GLP-1 receptors in the arcuate nucleus, paraventricular nucleus, and area postrema. Studies in diet-induced obese (DIO) rodent models has documented activation of anorexigenic pro-opiomelanocortin (POMC) neurons and suppression of orexigenic neuropeptide Y / agouti-related peptide (NPY/AgRP) neurons. This central effect is the principal driver of the body-weight phenotype observed in obesity studies.
• Gastrointestinal motility — delayed gastric emptying — GLP-1 receptor activation in vagal afferents and enteric neurons slows the rate of gastric emptying, reducing postprandial glucose excursions and prolonging satiety signals. Tachyphylaxis (partial desensitisation) of this effect develops over weeks of continuous receptor occupancy, which is why gastrointestinal tolerability typically improves with prolonged dosing in study models.

The C18 fatty diacid tether is what differentiates semaglutide pharmacokinetically from older GLP-1 analogs. By binding reversibly to serum albumin via this tether, semaglutide forms a circulating depot that protects it from renal clearance and DPP-4 degradation. Combined with the Aib⁸ substitution (which directly blocks the DPP-4 cleavage site at position 8–9), this gives semaglutide a half-life of 165 hours compared with liraglutide’s 13 hours and native GLP-1’s <2 minutes — a roughly 12× extension that enables once-weekly dosing schedules.

Published Evidence

Semaglutide is used in clinical contexts that investigate:

• Glucose homeostasis and insulin sensitivity — glucose-stimulated insulin secretion, oral and intravenous glucose tolerance tests, hyperinsulinaemic-euglycaemic clamps in db/db, ZDF, and high-fat-diet rodent models (Lau et al., J Med Chem 2015; Knudsen & Lau, Front Endocrinol 2019)
• Body weight and appetite regulation — food intake assessments, body composition (DEXA / MRI), respiratory exchange ratio in DIO and ob/ob mouse models; benchmark for novel anti-obesity peptide studies
• Cardiovascular and atherosclerosis studies — effects on endothelial function, plaque progression in ApoE^-/- and LDLR^-/- mice; mechanistic follow-up to the SUSTAIN-6 and PIONEER cardiovascular signal in clinical trials
• Renal protection and diabetic nephropathy models — albuminuria, glomerular filtration rate, mesangial expansion in streptozotocin-induced and Akita mouse diabetic kidney disease
• Neuroprotection studies — cognitive function, neuroinflammation, α-synuclein and amyloid-β pathology in Parkinson’s and Alzheimer’s preclinical models — GLP-1R is expressed throughout the CNS and is a current studies frontier
• Hepatic steatosis (MASLD/MASH) studies — liver triglyceride content, ALT/AST, fibrosis staging in choline-deficient and high-fat-high-fructose rodent diets
• Comparative metabolic peptide studies — benchmarking against newer multi-agonists. See the Retatrutide page for the triple GLP-1/GIP/glucagon comparator and the Retatrutide vs Tirzepatide guide for a dual-agonist side-by-side.

For broader context on where semaglutide fits within the metabolic-peptide landscape, see our peptides catalog and related compounds including Retatrutide (triple agonist) and Tesamorelin (GHRH analog for visceral adiposity).

Available Strengths and Concentrations

MedsBase stocks Semaglutide in seven lyophilized vial strengths to support both micro-dose titration studies and extended weekly-dosing protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:

All seven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume per administration or run extended multi-month protocols from a single vial.

How It Compares — Semaglutide vs Retatrutide vs Tirzepatide

Semaglutide, Retatrutide, and tirzepatide are the three most-cited long-acting incretin peptides in current metabolic support. They differ primarily in receptor selectivity: semaglutide is a single GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist. The escalating receptor profile correlates with progressively larger body-weight effects in DIO models but also broader off-target signalling.

For a full methodological comparison of the dual- vs triple-agonist literature, read Retatrutide vs Tirzepatide: triple vs dual agonist and Ozempic vs Mounjaro. Users selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide) against magnitude of effect (greater with dual- and triple-agonists).

Storage and Reconstitution

Before reconstitution: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized semaglutide is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder. Reconstitution procedure: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — ten units on a U-100 insulin syringe equals 250 mcg. Swirl gently — do not shake — and allow 2–5 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. After reconstitution: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because semaglutide is dosed once weekly in protocols, a single reconstituted 5 mg vial typically supports 4–8 weeks of titration studies depending on the target dose.

Frequently Asked Questions

What is Semaglutide used for in studies?

Semaglutide is used in studies investigating glucose homeostasis, insulin secretion, body weight and appetite regulation, gastric emptying, cardiovascular endpoints, renal protection in diabetic nephropathy models, hepatic steatosis (MASLD/MASH), and neuroprotection. It is the most extensively characterised long-acting GLP-1 agonist in the published literature and serves as the benchmark comparator for newer multi-agonist incretin peptides. The pharmaceutical-grade semaglutide sold here is not FDA-approved for human therapeutic use and is supplied strictly for clinical studies.

How is Semaglutide different from Retatrutide and Tirzepatide?

The key difference is receptor selectivity. Semaglutide is a single GLP-1 receptor agonist with the cleanest receptor pharmacology of the three. Tirzepatide adds GIP receptor activity (dual agonist). Retatrutide adds glucagon receptor activity on top of that (triple agonist). The escalating receptor profile produces progressively larger body-weight effects in published studies but also broader systemic signalling. Semaglutide remains the gold standard for glycaemic control and cardiovascular studies; multi-agonists are preferred where maximum body-weight effect is the studies endpoint.

What is the typical Semaglutide dose?

Published preclinical and clinical studies protocols typically use a titration schedule starting at 0.25 mg weekly and increasing by 0.25–0.5 mg every 4 weeks up to a maintenance dose of 1.0–2.4 mg weekly. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — ten units on a U-100 insulin syringe equals 250 mcg.

Is Semaglutide FDA approved?

Pharmaceutical semaglutide is FDA-approved under the brand names Ozempic, Wegovy, and Rybelsus for human therapeutic use in type 2 diabetes and chronic weight management, manufactured to GMP standards by Novo Nordisk.

How should Semaglutide be stored?

Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade the peptide. Protect from direct light at all times.

How do I reconstitute Semaglutide?

Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 2–5 minutes for full dissolution. Do not shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.

What strengths does MedsBase stock?

MedsBase carries Semaglutide in seven lyophilized vial strengths: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 50 mg. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.

What is the half-life of Semaglutide?

Semaglutide has an unusually long plasma half-life of approximately 165 hours (~7 days) following subcutaneous administration. This extended half-life is achieved by reversible binding to circulating serum albumin via the C18 fatty diacid tether at lysine 26, which protects the peptide from renal clearance. The long half-life enables once-weekly dosing schedules in published studies, in contrast to native GLP-1 (half-life under 2 minutes) and liraglutide (half-life ~13 hours).

Can Semaglutide and Tirzepatide be compared in studies?

Yes — head-to-head comparison is one of the most actively researched areas in metabolic peptide pharmacology. Published trials such as SURPASS-2 (clinical) and a growing body of preclinical work compare the two peptides on glycaemic control, body weight, gastric emptying, and cardiovascular endpoints. Semaglutide is typically the active comparator arm in newer multi-agonist trials because its single-receptor profile provides a clean baseline.

Does Semaglutide cause side reported effects?

The most consistent finding in semaglutide is gastrointestinal — nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4–8 weeks of continuous dosing as receptor tachyphylaxis develops. Less common findings in long-term studies include effects on gallbladder motility and (in rodent models with thyroid C-cell sensitivity) C-cell hyperplasia — the latter is a species-specific signal that has not translated to humans in long-term clinical follow-up.

What is the difference between subcutaneous and oral Semaglutide in studies?

Subcutaneous semaglutide (Ozempic, Wegovy) is the standard administration route because the peptide is rapidly degraded in the gastrointestinal tract. Oral semaglutide (Rybelsus) is co-formulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently raises gastric pH and protects the peptide long enough for it to cross the gastric mucosa. Oral bioavailability remains low (~1%), so studies-relevant oral doses are substantially higher than subcutaneous equivalents.

How long does Semaglutide take to show effects in preclinical studies?

Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1–2 weeks of weekly dosing and continue to accrue through 8–12 weeks. Maximum effect on body composition is typically observed after 16–20 weeks of continuous dosing in study models.

Can I order Semaglutide for international shipping?

Yes. MedsBase ships Semaglutide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy.

Other Peptides for Metabolic and Body-Composition Studies

• Retatrutide — Triple GLP-1/GIP/glucagon agonist (LY3437943) — the largest body-weight effect in current metabolic peptide studies
• Tesamorelin — GHRH analog — visceral adipose tissue and lipodystrophy studies
• CJC-1295 with DAC — Long-acting GHRH analog for growth-axis studies
• Ipamorelin — Selective GHRP for clean GH-axis pulse studies
• IGF-1 LR3 — Long-arginine IGF-1 analog — anabolic and regenerative support

Further Reading

More options in Peptides

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Retatrutide

US$150.00 – US$2,062.50Gama de preços: US$150.00 a US$2,062.50

Tirzepatide

US$105.00 – US$2,212.50Gama de preços: US$105.00 a US$2,212.50

BAC Water (Bacteriostatic Water)

US$50.00 – US$150.00Gama de preços: US$50.00 a US$150.00

HCG (Human Chorionic Gonadotropin) — Pharmaceutical Grade

US$255.00 – US$1,162.50Gama de preços: US$255.00 a US$1,162.50